|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Optimizing hepatitis C virus treatment through pharmacist interventions: Identification and management of drug-drug interactions显示文摘AIM To quantify drug-drug-interactions(DDIs) encountered in patients prescribed hepatitis C virus(HCV) treatment, the interventions made, and the time spent in this process.METHODS As standard of care, a clinical pharmacist screened for DDIs in patients prescribed direct acting antiviral(DAA) HCV treatment between November 2013 and July 2015 at the University of Colorado Hepatology Clinic. HCV regimens prescribed included ledipasvir/sofosbuvir(LDV/SOF), paritaprevir/ritonavir/ombitasvir/dasabuvir(OBV/PTV/r + DSV), simeprevir/sofosbuvir (SIM/SOF), and sofosbuvir/ribavirin (SOF/RBV). This retrospective analysis reviewed the work completed by the clinical pharmacist in order to measure the aims identified for the study. The number and type of DDIs identified were summarized with descriptive statistics.RESULTS Six hundred and sixty four patients(83.4% Caucasian, 57% male, average 56.7 years old) were identified; 369 for LDV/SOF, 48 for OBV/PTV/r + DSV, 114 for SIM/SOF, and 133 for SOF/RBV. Fifty-one point five per cent of patients were cirrhotic. Overall, 5217 medications were reviewed (7.86 medications per patient) and 781 interactions identified (1.18 interactions per patient). The number of interactions were fewest for SOF/RBV (0.17 interactions per patient) and highest for OBV/PTV/r + DSV (2.48 interactions per patient). LDV/SOF and SIM/SOF had similar number of interactions (1.28 and 1.48 interactions per patient, respectively). Gastric acid modifiers and vitamin/herbal supplements commonly caused interactions with LDV/SOF. Hypertensive agents, analgesics, and psychiatric medications frequently caused interactions with OBV/PTV/r + DSV and SIM/SOF. To manage these interactions, the pharmacists most often recommended discontinuing the medication (28.9%), increasing monitoring for toxicities (24.1%), or separating administration times (18.2%). The pharmacist chart review for each patient usually took approximately 30 min, with additional time for more complex patients. CONCLUSION DDIs are common with HCV medications and management can require medication adjustments and increased monitoring. An interdisciplinary team including a clinical pharmacist can optimize patient care. | Jacob A Langness Matthew Nguyen Amanda Wieland Gregory T Everson Jennifer J Kiser | 2017 | World Journal of Gastroenterology2017，23，9： | 5 |
| 2 | To surcharge or not to surcharge: An empirical investigation of ATM pricing 显示文摘 | Hannah T H Kiser E K Prager R A | 2003 | The Review of Economics and Statistics2003，85，4： | 1 |
| 3 | Treatment of hepatorenal syndrome显示文摘 | Kiser TH Maclaren R Fish DN | 2009 | Pharmacotherapy2009，29，10： | 1 |
| 4 | Plastic flow and fracture of a particulate metal matrix composite 显示文摘 | KISER M T ZOK F W WILKINSON D S | 1996 | Acta Mater1996，44，12： | 1 |
| 5 | Proton pump inhibitors and histamine-2 receptor antagonists in the intensive care setting:focus on therapeutic and adverse events显示文摘 | MacLaren R Kassel L E Kiser T H | 2015 | Expert Opin Drug Saf2015，14，2： | 1 |
| 6 | Blunt tracheobmnehial inju- ries : treatment and outcomes 显示文摘 | Kiser AC O'Brien SM Detterbeek FC | 2001 | Ann Thorac Surg2001，71，6： | 1 |
| 7 | Assessment of topical microbicides to prevent HIV-1 transmission:Concepts,testing,lessons learned显示文摘 | Friend DR Kiser PF | 2013 | Antiviral Res2013，99，3： | 1 |
| 8 | Reliability and consistency of visual acuity and contrast sensitivity measures in advanced eye disease显示文摘 | Kiser AK Mladenovich D Eshraghi F | 2005 | Optom Vis Sei2005，82，11： | 1 |
| 9 | A randomized, double-blind, placebo-controlled dose range study of dexmedetomidine as adjunctive therapy for alcohol withdrawal 显示文摘 | MUELLER SW PRESLASKI CR KISER TH et O1 | 2014 | Crit Care Med2014，42，5： | 1 |
| 10 | Evaluation of diagnostic tests and argatroban or lepirudin therapy in patients with suspected heparinqnduced thrombocytopenia 显示文摘 | Kiser TH Jung R MacLaren R et aI | 2005 | Pharmacotherapy2005，25，17： | 1 |
| 11 | A Randomized, Double-Blind, Placebo-Controlled Dose Range Study of Dexmedetomidine as Adjunctive Therapy for Alcohol Withdrawal*显示文摘 | Scott W. Mueller Candice R. Preslaski Tyree H. Kiser Douglas N. Fish James C. Lavelle Stephen P. Malkoski Robert MacLaren | 2014 | Critical Care Medicine2014，，5： | 1 |
| 12 | Efficient transfer for a glyphosate tolerance gene into tomato using a binary Agrobacterium tumefaciens vector显示文摘 | FILLATTI J J KISER J ROSE R | 1987 | Bio/Technology1987，5，： | 1 |
| 13 | Plastic flow and fracture of a particulate metal matrix composite显示文摘 | Kiser M T Zok F W Wilkinson D S | 1996 | Acta Mater1996，44，9： | 1 |
| 14 | Bivalirudin versus unfractionated heparin for prevention of hemofilter occlusion during continuous renal replacement therapy显示文摘 | Kiser TH MacLaren R Fish DN | 2010 | Pharmacotherapy2010，30，11： | 1 |
| 15 | Evidence - Based Practice in Child and Adolescent Mental Health Services 显示文摘 | Hoagwood K Burns B J Kiser L etc | 2001 | Psychiatric Service2001，，9： | 1 |
| 16 | The mechanical response of ceramic microballoon reinforced aluminum matrix composites under compressive loading 显示文摘 | KISER M HE M Y ZOK F W | 1999 | Acta Materialia1999，47，9： | 1 |
| 17 | Identification of a host protein essential for assembly of immature HIV-1 capsids 显示文摘 | ZIMMERMAN C KLEIN K C KISER P K | 2002 | Nature2002，415，6867： | 1 |
| 18 | The effect of iopinavir/ritonavir on the renal clearance of tenofovir in HIV infected patients显示文摘 | Kiser JJ Carten ML Aquilante CL | 2008 | Clin Pharmacol Ther2008，83，2： | 1 |
| 19 | Review and management of drug interactions with boeeprovir and telaprevir 显示文摘 | Kiser JJ Burton JR Anderson PL ct al | 2012 | Hepatology2012，55，5： | 1 |
| 20 | Measurement of paclitaxel in biological matrices: high-throughput liquid chromatographic-tandem mass spectrometric quantification of paclitaxel and metabolites in human and dog plasrna显示文摘 | Alexander M S Kiser M M Culley T | 2003 | J Chromatogr B Analyt Technol Biomed Life Sei2003，785，2： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员